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Original Article
Preventive treatment for migraine in
primary care, a population-based study
in the Netherlands
F Dekker1, JP Dieleman2, A Knuistingh Neven1, MD Ferrari3
and WJJ Assendelft1
Abstract
Background: Preventive treatment of migraine contributes to reducing the impact of migraine but its extent of use in
routine care is unknown.
Objective: The objective of this article is to assess current use, previous use, duration and course of preventive treatment
of migraine in Dutch general practice.
Methods: We conducted a retrospective cohort study, for the period between 1997 and 2007, in the Interdisciplinary
Processing of Clinical Information (IPCI) database, a GP research database in the Netherlands (source population of
more than half a million subjects). All prevalent and incident migraine patients (N¼ 7367) were included.
Results: About 13% of all migraine patients currently use preventive therapy and almost half of migraine patients have
prior use. Of those starting with preventive treatment, 56% (95% CI: 54.3–64.7) still used it after nine months. There was
a long delay between migraine diagnosis and preventive treatment start. Forty-four percent (95% CI 43.0–45.7) started
preventive therapy in the study period.
Conclusion: This large primary-care database study shows that a limited number of patients are current users of pre-
ventive treatment, but many patients have prior use. After diagnosis there is often an extended time before preventive
treatment is applied. Also there is often only one attempt. The continuation in time seems appropriate. Preventive
therapy in migraine still deserves focus.
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Introduction
Migraine is a common, chronic, incapacitating neuro-
vascular disorder characterized by attacks of severe
headache, autonomic nervous system dysfunction, and
in some patients, an aura involving neurological symp-
toms (1). The mean one-year prevalence of migraine in
adults aged 18–65 years is more than 10% (10.9% in
the Americas and 14.8% in Europe) (2).
An important treatment goal is reducing the attack
frequency. Preventive treatment includes beta blockers
and anti-epileptics and is recommended in guidelines
(3–6). In the Netherlands preventive treatment with
propranolol or metoprolol is recommended for
patients with an attack rate of two or more attacks
per month (3,4).
Several studies into preventive treatment for
migraine suggest large under-treatment. A telephone
survey in the United States (US) showed that only 13%
of migraine patients who qualified for preventive treat-
ment actually received treatment (7,8). An earlier ques-
tionnaire study showed similarly low numbers (5% and
12.4%) for preventive treatment use (9,10), although an
additional 17.2% of patients used medication with
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potential antimigraine effects for other indications (10).
In France use of preventive treatment was estimated at
6% (11). In a small Dutch study in general practice
(GP), 8% of migraine patients used preventive medica-
tion (12). Recently, we described a Dutch pharmacy
record study comprising 6.2 million people, showing
that 19% of the triptan users at some time also take
preventive medication (13). Most studies on preventive
migraine treatment use suffer from methodological
shortcomings and differ among each other. In phar-
macy records, the indication for drug prescribing is usu-
ally lacking, as a result of which the medication may be
prescribed for other reasons (like hypertension).
Questionnaire studies in the general population also
may have included inappropriate migraine diagnoses
and misclassify frequent attack treatment as preventive
treatment (11).
For patients, the frequency of migraine attacks is the
most important consideration in the decision for pre-
ventive treatment (12). Preventive treatment is also
indicated when exuberant use of attack medication is
imminent and when there is a risk of medication-over-
use headache (MOH), which has a population preva-
lence of 4% in adults (14,15). Data on triptan use in the
Netherlands suggest that triptans possibly cause more
headaches than they cure (13).
For policy-making and optimizing routine care, a
valid estimate of the proportion of migraine patients
receiving preventive treatment is necessary. We
performed a population-based cohort study in a GP
research database in the Netherlands to gain




The study was conducted using the Integrated Primary
Care Information (IPCI) database, a longitudinal GP
research database in the Netherlands. The IPCI data-
base is maintained by the Department of Medical
Informatics of the Erasmus MC, University Medical
Centre Rotterdam in the Netherlands. The database
contains longitudinal data from computer-based
patient records of more than 150 GPs throughout
the Netherlands. Presently, the database comprises
data on more than 800,000 subjects, of whom the
age and gender distribution is similar to the Dutch
population. The registration uses the International
Classification of Primary Care (ICPC) (16,17) to regis-
ter patient symptoms and diagnoses, although these
can also be entered as free text. Prescription data
include product name, quantity dispensed, dosage
regimens, strength and indication. As of 1996, drugs
are coded according to the Anatomical Therapeutic
Chemical (ATC) classification scheme recommended
by the World Health Organization (WHO) (18). GPs
who participate in the IPCI project are not allowed to
use paper-based records.
The IPCI database system complies with European
Union guidelines on the use of medical data for medical
research and has been proven valid for pharmaco-epi-
demiological research (19). The Scientific and Ethical
Advisory Group of the IPCI project approved the study
(number 05/92).
Study period and study population
We used data of all individuals with at least one year of
follow-up data available in the database between
January 1996 and December 2007 (n¼ 478,584). One
year of data was needed to validly assess medical his-
tory and treatment history. Study entry was defined as
the date at which one year of follow-up was accumu-
lated or January 1, 1996, whichever was latest. Follow-
up lasted until the end of the study period, end of
patient registration with GP practice, death or last
IPCI data delivery, whichever came first. Within the
study population we identified a sub-cohort of patients
with newly detected migraine (incident diagnosis).
Ascertainment of migraine
GPs have a diagnostic code for migraine (ICPC-code
N89). Additional potential cases were identified in the
database through an inclusive string search on free text
(‘migrain*’). The presence and date of diagnosis of
migraine were evaluated by a manual review of the
electronic patient record (EPR) of all the potential
cases by the principal investigator (FD). Our case def-
inition relied on the International Headache Society
(IHS)-classification (20). As typical migraine symptoms
we considered attack frequency, duration of the head-
ache, (unilateral) location, pulsating quality, moderate
or severe pain intensity, aggravation by or causing
avoidance of routine physical activity (e.g. walking or
climbing stairs), nausea or vomiting, photophobia and
phonophobia, and the existence of precipitating aura,
shooting, or burning pain. We accepted GP diagnoses if
they recurred in the patient record and if typical
migraine symptoms were present.
The index date was defined as the date of diagnosis
of migraine. If the index date was on or after the start
of follow-up, the migraine was classified as incident. In
other cases the migraine was considered as prevalent.
We distinguished two categories of migraine as
abstracted from the database, namely ‘‘uncertain
migraine’’ and ‘‘certain migraine.’’ Uncertain migraine
comprised patients who expressed symptoms of
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migraine or had sporadic attacks, or were labeled by
the physician as having migraine, but visited the GP
only once for that reason. These patients had incom-
plete symptoms or were only once indistinctly asso-
ciated with migraine in the whole research period
(no preventive therapy). Uncertain migraine was
not included in our analysis. This category has to be
distinguished from ‘probable migraine’ from the IHS
classification (20). Migraine was classified as ‘‘certain
migraine’’ if the headache features corresponded to
the IHS criteria for migraine (20). We further detailed
certain migraine according to presence of aura and
considered menstrually related migraine (MRM) as a
subgroup of certain migraine. Patients with typical aura
without headache (AWoH) and patients with MOH
were considered separate from certain migraine.
Migraine treatment
Treatment details extracted from the database com-
prised the date of prescribing, full ATC code, drug
name, strength, dose instructions and primary indica-
tion for the prescription. As attack treatment we con-
sidered drugs mentioned in Dutch guidelines
(paracetamol, acetylsalicylic acid, nonsteroidal anti-
inflammatory drugs (NSAIDs), triptans, ergots) and
as preventive treatment we considered agents that are
mentioned in Dutch guidelines or are officially
approved preventive treatment (beta blockers without
intrinsic sympathomimetic activity, valproic acid, topir-
amate, pizotifen, amitriptyline and flunarizine) (3,4).
Analysis
We calculated age- and gender-specific incidence rates
of different types of migraine by dividing the number
of incident cases by the total accumulated follow-up
time. Ninety-five percent confidence intervals (95%
CI) were calculated assuming a Poisson distribution.
We used Kaplan-Meier analysis to calculate the time
to preventive treatment start following migraine diag-
nosis in patients who had not used any of the prevent-
ive treatment agents before. Kaplan-Meier analysis
was also used to estimate the 11-year cumulative inci-
dence of treatment initiation following migraine
diagnosis.
To assess duration of treatment we assessed the pro-
portion of patients still using the initial medication in
periods of three, six, nine and 12 months following
treatment start. Proportions were calculated by divid-
ing the number of patients remaining on initial treat-
ment by the number of patients still in follow-up at the
end of the concerned period. All the analyses were con-
ducted using SPSS for Windows version 15.0 (SPSS
Inc, Chicago, IL, USA).
Results
The total amount of follow-up time for the 472,033
subjects in the study population without migraine at
baseline was 1,855,904 person years, with an average
of 3.9 person years per subject (standard deviation
(SD): 2.99). We identified 7525 first-time diagnoses of
migraine or related headache disorders, of which 5134
were certain migraine, 2081 uncertain migraine, 152
AWoH and 158 MOH (Figure 1). MRM was found
in 712 patients (Table 1). Migraine patients were pre-
dominantly female (75%) and mostly between 30 and
40 years of age (Table 1). The overall incidence rate of
migraine over the entire study period, including uncer-
tain cases, was 4.05 per 1000 person years (95% CI:
3.96–4.15). Considering certain migraine only, the
incidence rate was 2.8 per 1000 person years (95%
CI: 2.7–2.8).
Treatment of migraine
Out of 5134 migraine patients, 684 (13.3%, 95% CI:
12.4–14.3) received a preventive treatment prescription
at any time during the study period, most of them with-
out ever receiving attack treatment in the study period
(no attack treatment out of 684: n¼ 501, 73.2%, 95%
CI: 69.7–76.5) and consisting of a single type (n¼ 552,
80.7%, 95% CI: 77.5–83.6). Of all patients receiving
preventive therapy, 21 patients (3.1%, 95% CI: 2.0–
4.7) had two or more preventive therapies (Figure 1).
Among patients diagnosed as having migraine with
aura, 11.2% (95% CI: 9.40–13.30) were prescribed pre-
ventive treatment. Migraine patients without aura
receiving preventive treatment comprised 13.2% (95%
CI: 8.3–20.1), and in patients for whom the presence of
aura was not mentioned, the percentage of those receiv-
ing preventive treatment was 13.1% (95% CI: 12.1–
14.2). The odds ratio (OR) for having received prevent-
ive treatment in patients with aura versus patients not
having aura or aura not specified was 0.87 (95% CI:
0.70–1.08)). AWoH was recorded for 152 cases, of
whom 24 (15.8%, 95% CI: 10.6–222.8) received pre-
ventive treatment (Table 2).
Of the 1936 migraine patients using triptan, 92
(4.8%, CI: 3.87–5.52) also used preventive medication.
Of the 1080 NSAID users, 45 (4.2%, 95% CI: 3.09–
5.58) also had preventive medication.
The average age for those receiving prescribed attack
treatment was 38.1 (SD 14.6) years and for preventive
treatment 42.3 (SD 15.4) years.
The Kaplan-Meier analysis showed that first-time
preventive treatment prescriptions were issued mostly
within the first two years following diagnosis but con-
tinued to be issued at a lower steady rate thereafter
(Figures 2 and 3). The cumulative incidence of ever
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Figure 1. Process of identification of preventive migraine cases in the Integrated Primary Care Information (IPCI) database.
n: number; MOH: medication-overuse headache; AWoH: aura without headache.










Total N¼ 2,340,980 n (%) N¼ 7367 n (%) N¼ 2081 n (%) N¼ 4975 n (%) N¼ 712 n (%) N¼ 152 n (%) N¼ 158 n (%)
Sex
Male 1,162,830 (49.7) 1859 (25.2) 566 (26.7) 1213 (24.4) – 55 (36.2) 25 (15.8)
Female 1,178,150 (50.3) 5508 (74.8) 1515 (72.3) 3762 (75.5) 712 97 (63.8) 133 (84.2).
Age
0–10 247,506 (10.6) 258 (3.5) 90 (4.3) 167 (3.4) – 1 (0.7) –
10–19 274,523 (11.7) 880 (11.9) 256 (12.3) 607 (12.2) 36 (5.1) 5 (3.3) 12 (7.6)
21–29 321,827 (13.7) 1388 (18.8) 396 (19.0) 947 (19.0) 135 (19.0) 12 (7.9) 33 (20.9)
31–39 391,838 (16.7) 1826 (24.8) 497 (23.9) 1238 (24.9) 288 (40.4) 34 (22.4) 57 (36.1)
41–49 361,684 (15.5) 1665 (22.6) 450 (21.6) 1162 (23.4) 220 (30.9) 30 (19.7) 23 (14.6)
51–59 303,424 (13.0) 872 (11.8) 249 (12.0) 557 (11.2) 33 (4.6) 39 (25.7) 27 (17.1)
61–70 270,737 (11.6) 294 (4.0) 83 (4.0) 191 (3.8) – 16 (10.5) 4 (2.5)
71þ 169,441 (7.2) 184 (2.5) 61 (2.9) 106 (2.1) – 15 (9.9) 2 (1.3)
aMRM: Menstrually related migraine is a subgroup of certain migraine. bAWoH: typical aura without headache. cMOH (medication-overuse headache) is
not part of the total migraine (¼all certain migraine).
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having used preventive treatment within a study period
of 11 years (average 3.9 person years (SD: 2.99)) was
44.3% (95% CI: 43.0–45.7). For women this was 47.0%
(95% CI 43.4–48.6) and for male 36.1% (95% CI:
33.4–38.9).
The average time lapse between starting attack treat-
ment and starting preventive treatment was 4.3 years
during this 11-year study period. Patients started pre-
ventive migraine treatment at a high average age: 38.1
for males and 42.3 years for females.
Among patients starting preventive treatment, many
had discontinued that treatment within three months,
after which the percentage of users stabilized. The aver-
age proportion of patients still using preventive treat-
ment after nine months of first start was 55.6% (95%
CI: 54.9–60.1) but varied widely by treatment. Patients
using beta blockers were most likely to continue treat-
ment (59.6% after nine months, 95% CI: 54.3–64.7)
whereas patients using pizotifen were least likely to con-
tinue (37.0% after nine months, 95% CI: 26.2–49.1).
Among patients using beta blockers, prolonged use
after nine months was 77.8% (95% CI: 62.5–88.3) for
atenolol, 62.6% (95% CI: 53.4–71.0) for metoprolol
and 50.3% (95% CI: 42.6–58.0) for propranolol. For
patients using amitriptyline or valproic acid, the num-
bers were too small to make reliable estimates.
We also studied the extent to which patients contin-
ued to use initial, prescribed attack treatment. The drop
in attack treatment use was much larger than the drop
in preventive treatment. After nine months the propor-
tion still receiving prescriptions for a triptan was 26.7%
(95% CI: 20.4–34.3) (not available over the counter
(OTC) in the Netherlands) and for NSAIDs, 26.8%
(95% CI: 24.5–29.3) (available OTC).
Discussion
In a large Dutch longitudinal GP research database we
found that the percentage of all migraine patients
receiving preventive treatment in the Netherlands was
13.3% (95% CI: 12.4–14.3). Approximately 56% of
those starting preventive treatment continued on it for
a prolonged period of time (i.e. nine months), suggest-
ing good treatment effect and acceptable side effects.
The duration of first preventive treatment use was
much longer than that for first attack treatment. In
the vast majority of patients only one type of preventive
treatment was tried, which may be because the current
guideline recommends only beta blockers as preventive
treatment (3).
The large time lapse between starting attack- and
preventive treatment of 4.3 years and the high average
Table 2. Use of preventive treatment in migraine.
Migraine (certain)
AWoH MOHAlla
With and without aura
MRM
Unspecified MAþ MA (subgroup)
Total 5134 3989 1053 144 712 152 158
preventive (%) 684 (12.9) 523 (13.1) 118 (11.4) 19 (13.2) 72 (3.8) 24 (15.79) 15 (9.5)
Specification preventive medication
Propranolol 240 (35.1) 192 (36.7) 38 (32.2) 6 (31.6) 12 (44.4) 4 (16.7) 7 (46.7)
Metoprolol 177 (25.9) 133 (25.4) 31 (26.3) 3 (15.8) 7 (25.9) 1 (41.7) 2 (13.3)
Other beta blockers 87 (12.7) 59 (11.3) 21 (18.8) 1 (5.3) 4 (14.8) 6 (25.0)
AII-antagonists 7 (1.1) 6 (1.1) 1 (0.8) – – – –
Verapamil 6 (0.9) 5 (1.0) 1 (0.8) – – – –
Valproic acid 16 (2.3) 8 (1.5) 4 (3.4) 3 (15.8) – 1 (4.2) 2 (13.3)
Topiramate 2 (0.3) 2 (0.4) – – – – –
Pizotifen 80 (11.7) 63 (12.0) 16 (13.6) 1 (5.3) – – 2 (13.3)
Clonidine 29 (4.4) 23 (4.4) 2 (1,7) 4 (21.1) 1 (3.7) 1 (4.2) –
Flunarizine 9 (1.3) 7 (1.3) – – 1 (3.7) 2 (83)
Methysergide 3 (0.4) 2 (0.4) 1 (0.8) – – – –
Amitriptyline 36 (5.3) 31 (5.9) 4 (3.4) 1 (5.3) 2 (7.4) – 2 (13.3)
Numbers of patients (percentage). MAþ: migraine with aura; MA: migraine without aura; MRM: menstrually related migraine (as mentioned in
electronic patient record (EPR), both regular and pure); AWoH: typical aura without headache (migraine sans migraine); MOH: medication-overuse
headache. aWithout AWoH, including MOH.
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age at start (male 38.1 and female 42.3 years) indicates
that at the start of preventive therapy the burden of
migraine often is already past its highest peak through-
out life (1). This underlines the reluctance to accept the
daily use of preventive medication (21).
The number of new patients receiving preventive
treatment remained stable over the study years. And
as the incidence of new cases of migraine decreased
over the years, there was a relative increase in the use
of preventive treatment (data not shown).
We found no significant differences in migraine
treatment prescribing between different types of
migraine, or between presence and absence of aura.
Neither did we find a relation between prescribing of
preventive treatment and that of attack treatment (see
Figure 1); only a small proportion of patients receiving
preventive treatment also received prescriptions for
attack treatment.
The attack frequency at which patients are recom-
mended to start preventive therapy varies widely in
guidelines (22,23). The Dutch guidelines recommend
preventive therapy in case of two or more attacks per
month in primary care (3) or advise preventive treat-
ment in case of three of more attacks per month in
secondary care (4).
Our rate of 13% preventive treatment is in line with
studies in other countries (7,9–12,24–27).
Some studies, however, reported a lower frequency
of use (25,28). Others have estimated that 5%–83% of
migraine patients qualify for preventive treatment
(8,10,29). One study in the same population as ours
claims much higher numbers for prevention (30).
However, this study was performed in a high selective
population of patients referred to a neurologist and as
the presented data do not correspond with previous
studies (12,24,25), this study is of questionable import-
ance with which to compare preventive treatment.
Our study period covers 11 years with an average of
3.9 person years’ availability, whereas most previous
studies reported the actual number of patients per
year. It shows that when cumulated over a longer
period many more patients, 44.3% of all patients,
have tried preventive treatment, which is well above
previous estimates (7,9–12,24–27).




























Figure 2. Kaplan-Meier graph of start of preventive treatment related to time after first diagnosis of migraine.
One minus cumulative survival curve of the time span between initial migraine diagnosis and the start of preventive treatment, and the
difference between males and females. 01: male, 02: female. Time is shown in days after initial diagnosis of migraine.
6 Cephalalgia 0(0)
XML Template (2013) [20.5.2013–12:46pm] [1–9]
//blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/CEPJ/Vol00000/130124/APPFile/SG-CEPJ130124.3d (CEP) [PREPRINTER stage]
In the recent study by Berger et al., based on a US
health insurance claims database, continued use was
lower. For example, for beta blocker use after six
months, continued use was 43.1%, compared to
59.6% in ours. However, there were various differences
with our study. We used the volume of prescriptions,
not only the simple amount of prescriptions. Our inclu-
sion is based on a validated method for diagnosis; their
inclusion was based also on medication use as such
(leading to higher numbers of patients). Finally, their
research period was shorter (two years) (28).
Preventive treatment is prescribed to only 4.8% of
triptan users and to 4.2% of NSAID users (applies only
to prescribed medication, not to OTCs). This finding
differs from other studies in which triptan users have
more preventive medication (13,25). However, other
studies are usually not based on clinical diagnosis.
In this study, using observational primary-care
information, misclassification of migraine may have
occurred. False-negative misclassification could have
occurred if patients did not seek GP attention or if
they were treated solely by a specialist. As neurologists
in the Netherlands are treating 3% of migraine
patients, the possibility of under-presenting of severe
migraine patients will likewise only be small (13).
Of the 478,585 eligible people in the database, we
identified 7525 certain and possible new migraine
patients at an incidence rate of 4.05 per 1000 person
years. These findings may not apply to the overall
migraine population. In the EPR many characteristics
of migraine, such as the presence of aura and relation to
the menstrual period, is often insufficiently described.
This most likely explains the low proportion of patients
with aura (20.5%) and the probable under-reporting of
MRM migraine (9.1%) and typical AWoH (3.0%).
As preventive treatment for AWoH is not applicable
or controversial, we did not include this diagnosis in
our study. However, we included MOH, since we had
sufficient observation time for each subject to reliably
assess the temporal relationship between medication
overuse and diagnosis of migraine (usually migraine,
rarely tension-type headache, as recorded in the
EPR). Including patients with MOH in the analysis
may have caused some contamination by tension-type
headache but, given the numbers, it will not have a
major impact on the estimates.
This study shows a long-lasting and continued use for
nine to 12 months of preventive medication in 56% of
patients starting on preventive medication for migraine.
Although this real-life study cannot be compared with
studies in an experimental setting, in our study the fre-
quency of treatment withdrawal is much higher, espe-
cially for beta blockers (31). In usual care treatment
withdrawal can be interpreted, at least for a part, as
non-response. The response rate in experimental trials
is around 50%, which is in line with the withdrawal rate
in our study (31). The guideline compliance in our study
was much better than in an older study (1995–1998) (25).
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Figure 3. The course of preventive treatment.
Each line represents a preventive treatment. On the X-axis the total number of patient in follow-up is shown. n: number.
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The absence of differences in treatment patterns
between types of migraine and between population sub-
groups suggests that this study gives no indication of
extra attention in the area of preventive treatment for
any specific group of patients.
Despite many efforts to improve the treatment of
migraine and an otherwise well-used headache guide-
line in the Netherlands that promotes preventive treat-
ment, there is much room for improvement. The
compliance with treatment guidelines has improved,
but the actual number of patients on preventive treat-
ment remains low.
Qualitative research could give more insight into the
reasons behind the limited use of preventive medication
in younger migraine patients, the extended duration
between diagnosis and start of preventive treatment,
and why and how prescribed attack treatment interferes
with preventive treatment (e.g. whether patient and
physicians accept only one treatment for one illness at
the same time).
This may point the way toward better explanation
and defense of preventive treatment to expand its use,
as well as encouraging more than one attempt using
alternative medication.
Although compliance with preventive treatment has
improved and many patients have experience with it,
preventive treatment still needs attention in primary
care. Further research into the underlying reasons and
motives of patients and physicians is desirable. Firstly,
the greatest gain would be made if more patients would
consult their GPs when they have migraine attacks,
thereby leading to more migraine diagnoses.
Secondly, more and/or repeated diagnoses followed
by actively inviting migraine patients for a personal
consultation to discuss preventive treatment would
lead to even more improvement.
Clinical implications
. A limited number of patients are current users of preventive treatment (13%), but many patients have prior
use (44%).
. After diagnosis there is often an extended time before preventive treatment is applied, on average more than
four years.
. Often there is only one attempt at preventive therapy.
. The continuation in time of preventive treatment equals study level.
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